Oncolytics Biotech Inc ONCY

Roche in-licenses USP-1 small molecule to PARP inhibitor

[Noteable]

July 13, 2023 - " USP1 is one of a clutch of emerging targets for synthetic lethality, an approach to killing cancer cells that PARP inhibitors such as AstraZeneca and Merck & Co.’s Lynparza have helped put on the map over the past decade. While PARP inhibitors have validated the concept, they are unable to trigger responses in all patients and are vulnerable to resistance even when they are initially effective. Roche has identified the candidate as a good fit for its pipeline. "

https://www.fiercebiotech.com/biotech/roche-finds-usp-cancer-inking-deal-ksq-expand-stable-synthetic-lethal-candidates

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420636/

[Noteable]

Prior to the signing of the Inflation Reduction Act (IRA) in August 2022 Big Pharma was actively pursuing small molecule acquisition and development. With the passage of the IRA, small molecules were provided 9 years of FDA marketing exclusivity while biologicals were provided 13 years to FDA marketing exclusivity on the date of FDA approval. Now Big Pharma is seeking to transition their

[Noteable]

The IRA also sets out differential treatment for large molecule versus small molecule products, with injectables being better insulated from the the Drug Price Negotiation Program  (DPNP) than pills. Large molecule drugs cannot be selected for  DPNP for 13 years from the date of their FDA approval, whereas small molecule drugs can be selected after 9 years from the date of

[Noteable]

And as previously stated, it looks like Roche/Genentech doesn't have a good understanding of the impact of the IRA  on their present business model...  https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=35532286

[Noteable]

Like Pfizer, Roche is expanding its reach into the oncology space that ONCY's pelareorep can synergistically facilitate in gaining effectiveness.